Vaccizone selects Exothera for process development and GMP manufacturing of its SARS CoV 2 vaccine based on proprietary ASC technology Kumar Jeetendra | July 14, 2022 Istanbul (Turkey) – 6th July 2022 – Life Science Newswire – Vaccizone, a vaccine development company focusing on innovative antigen delivery technology, selected Exothera S.A. to fast-track process development of its SARS CoV 2 vaccine for European clinical trials. Vaccizone has developed and patented a novel method for delivering antigens and bioactive compounds which can …
